Investor Relations

Charles River provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions around the globe accelerate their research and drug development efforts. Our dedicated employees are focused on providing clients with exactly what they need to improve and expedite the discovery, early-stage development and safe manufacture of new therapies for the patients who need them.

CR-000172

News Release

 View printer-friendly version

Charles River Laboratories Holdings Announces Filing Of Registration Statement For Initial Public Offering Of Common Stock
Charles River Laboratories Holdings, Inc.,a leading provider of critical research tools and integrated support services that enable innovative and efficient drug discovery and development, announced today that it has filed a registration statement with the Securities and Exchange Commission for a proposed initial public offering of its common stock.

Donaldson, Lufkin & Jenrette Securities Corporation and Lehman Brothers Inc. will act as lead managing underwriters for the offering and ING Barings LLC, SG Cowen Securities Corporation, U.S. Bancorp Piper Jaffray Inc. and DLJdirect Inc. will act as co-managing underwriters. Net proceeds from the offering are expected to be used to pay down indebtedness. All shares in the offering are expected to be sold by Charles River.

A registration statement relating to these securities has been filed with the Securities and Exchange Commission but has not yet become effective. These securities may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective. This press release does not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any State in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such State.

When available, a copy of the preliminary prospectus may be obtained from the offices of Donaldson, Lufkin & Jenrette Securities Corporation, 277 Park Avenue, New York, NY 10172, 212-892-3000, or by contacting any of the other managing underwriters.

Featured Report

2018 Annual Report (PDF)

Investor Hotline

877-567-6CRL (6275)